# Admera Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/admera-health

- Industry: Healthcare
- Headquarters: South Plainfield, US
- Website: www.admerahealth.com
- Latest round: Series A (Apr 7, 2015)
- Investors on record: 2

## About

Admera Health is a genomic services company focused on providing advanced solutions such as Next Generation Sequencing (NGS) and bioinformatics analysis to clients in the biotech, pharmaceutical, and academic sectors.Founded in 2012 and headquartered in South Plainfield, US, Admera Health specializes in genomic services. The company has undergone strategic pivots to enhance its service offerings without any notable structural changes. The CEO, Yun Zhao, has a background in founding other ventures that contribute valuable expertise to the company.Admera Health specializes in offering advanced genomic services, including Next Generation Sequencing (NGS), bioinformatics analysis, and various applications such as transcriptomics, epigenomics, and metabolomics. Their core product offerings enable clients to process and analyze genetic data efficiently, catering to diverse needs within the biotech, pharmaceutical, and academic research sectors. Admera Health has developed optimized workflows to handle challenging samples, including those with ultra-low input, making their services highly adaptable for projects ranging from ancient DNA analysis to contemporary human exome sequencing. Their clientele includes renowned institutions like Duke University and Stanford University, indicating a strong foothold in the North American market while also extending their services to customers in Europe and Asia.Admera Health's revenue model primarily revolves around B2B transactions, providing tailored genomic solutions to research institutions, biotechnology firms, and pharmaceutical companies. The company engages in direct partnerships with clients, often structuring contracts that include both one-time service fees and ongoing collaborations for larger projects. Pricing plans are based on the complexity and scale of the services rendered, with specific offerings designed to meet the unique demands of various research initiatives. The company's flagship services, including high-throughput gene expression and custom sequencing solutions, are instrumental in driving client engagement and fostering long-term relationships, thereby contributing to a sustainable revenue stream.Admera Health's future growth strategy includes the development of new genomic products, although specific release dates are not disclosed. The company aims to expand its market presence into Europe and Asia, leveraging recent funding from Himile Capital to support this initiative. Details of the financial deal were not disclosed, but the investment will aid in bolstering their service reach and enhancing product offerings.

## Funding rounds

- Series A, Apr 7, 2015 — YuanBio Venture, Prime Value Capital

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Prime Value Capital (https://capitalatlas.ai/funds/prime-value-capital) — Series A